Core Viewpoint - Zhaoke Ophthalmology-B (06622.HK) experienced a significant stock price increase, rising 8.6% to HKD 3.41, marking a new high since October 13 and an overall increase of over 1.8 times in the year [1] Company Developments - Zhaoke Ophthalmology has entered into a distribution and supply agreement with leading Indonesian pharmaceutical company PT Ferron for the commercialization of BRIMOCHOL™PF in Indonesia, an innovative drug licensed from enpoint for the treatment of presbyopia [1] - Under the agreement, Zhaoke Ophthalmology grants PT Ferron exclusive rights to import, promote, distribute, market, and sell the product in Indonesia [1] - The company will receive an upfront payment and may earn additional milestone payments based on specific achievements [1]

Core Viewpoint - The company has entered into a distribution and supply agreement with PT Ferron, a leading pharmaceutical company in Indonesia, for the commercialization of BRIMOCHOL™PF, an innovative drug for treating presbyopia [1] Group 1: Agreement Details - The agreement grants PT Ferron exclusive rights to import, promote, distribute, market, and sell BRIMOCHOL™PF in Indonesia [1] - The company will receive an upfront payment and may earn additional milestone payments based on specific achievements [1] Group 2: Product Information - BRIMOCHOL™PF is a preservative-free, experimental eye drop administered once daily to correct age-related near vision loss [1] - The drug developer, Tenpoint, announced that the FDA has accepted the new drug application for BRIMOCHOL™PF, with a review deadline set for January 28, 2026 [1] Group 3: Clinical Study - BRIO-II is a three-arm, multi-center, randomized, double-blind study assessing the safety and efficacy of BRIMOCHOL™PF compared to other treatments, involving 629 participants across 47 trial centers in the U.S. [1]